News

Unleashing the power of patriots
Enlarge image

FundingUKFrance

Unleashing the power of patriots

04.09.2012 - The Bioindustry Association suggests to create a fund that allows Britons to invest in innovative small companies in their home region.

When an idea from France is worth considering in the UK it has to be indeed ground-breaking. London-based Bioindustry Association (BIA) published on 3 September a new report that proposes the creation of a so-called „Citizen’s Innovation Fund“ (CIF). The concept is based on the French „Fonds Communs de Placements dans l’Innovation“ (FCPI) that has raised over €6bn since 1997. The basic idea is to fuel funding of small companies by offering investors tax advantages that, according to BIA Chief Executive Officer Steve Bates, „would allow members of the public to put up to £15,000 a year into a fund for dragons’ den-style experts to invest in innovative companies – with a tax break if they keep their money invested for five years.“ By investing in local enterprises, the CIFs would improve the British public’s engagement in the economic development of their homeland.

The BIA estimates that £300m a year could be unlocked. The money would allow the companies to grow faster and pay taxes sooner than otherwise possible. The government’s expenditures would be levelled within three years and as a side effect over 1,500 new jobs could be created.

http://www.european-biotechnology-news.com/news/news/2012-03/unleashing-the-power-of-patriots.html

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Immuno-oncologyNetherlandsBelgium

21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.

RegulatorySwitzerlandEU

20.04.2016 The US government is forking out up to US$100m to get Basilea Pharmaceutica’s broad-spectrum antibiotic ceftobiprole on the US market. In the EU, ceftobiprole is already available.

Immuno-oncologyUK

19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.

FinancingSwitzerlandFranceEUGermanyDenmark

15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.

Event ReviewSwitzerlandBelgiumEU

13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.

FinancingGermanyNetherlandsEU

12.04.2016 German-Dutch life science investment specialist Forbion Capital Partners has raised more than €180m for its venture capital fund Forbion Capital Fund III. Once more the money will primarily go to European start-ups.

Event ReviewGermanyEU

08.04.2016 Do you win by being innovative?, was the question asked at this year’s DIA Euromeeting in Hamburg. In a relaxed and cooperative atmosphere, regulators, physicians and patients had ample opportunity to interact with the healthcare industry.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

München

BioVaria 2016

Berlin (GER)

XIV. BIONNALE 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • IMMUNICUM AB (S)29.80 SEK12.88%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.33%
  • BIONOR PHARMA (N)0.73 NOK-7.59%
  • ACTIVE BIOTECH (S)10.20 SEK-5.12%

TOP

  • AB SCIENCE (F)17.91 EUR62.8%
  • SYNAIRGEN (UK)35.75 GBP45.9%
  • BIOFRONTERA (D)3.19 EUR36.9%

FLOP

  • THERAMETRICS (CH)0.02 CHF-50.0%
  • SERODUS (N)1.41 NOK-31.2%
  • OREXO (S)48.80 SEK-21.3%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)30.50 SEK1974.8%
  • NICOX (F)8.88 EUR369.8%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.30 SEK-87.6%
  • BB BIOTECH (D)46.44 EUR-82.3%
  • BIOTEST (D)16.65 EUR-76.5%

No liability assumed, Date: 02.05.2016